ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1849

Cost-related Prescription Non-adherence Is Associated with Patient-reported Outcomes of Systemic Lupus Erythematosus Activity and Damage: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort

Deeba Minhas1, Wendy Marder 2, Sioban Harlow 3, Hanna Saltzman 3, Afton Hassett 3, Suzanna Zick 3, Lu Wang 3, Kamil Barbour 4, Charles Helmick 5, Caroline Gordon 6, W. Joseph McCune 1 and Emily Somers 3, 1University of Michigan, Ann Arbor, MI, 2Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, 3University of Michigan, Ann Arbor, 4Centers for Disease Control and Prevention, Atlanta, 5Centers for Disease Control and Prevention, Division of Population Health, Atlanta, GA, 6University of Birmingham, Birmingham, United Kingdom

Meeting: ACR/ARP Annual Meeting 2019

Keywords: health disparities, Lupus, medication access and Disease Activity, non-adherence

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M110: Healthcare Disparities in Rheumatology (1848–1853)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Medication access and adherence play key roles in determining patient outcomes.  We investigated whether cost-related non-adherence (CRNA) to prescription medications was associated with worse patient-reported outcomes in a population-based SLE cohort.

Methods: This study utilized baseline data from the Michigan Lupus Epidemiology & Surveillance (MILES) Cohort. We collected detailed clinical, medication, and sociodemographic data through structured interviews and validated questionnaires. We used validated patient-reported outcome measures of SLE activity (Systemic Lupus Activity Questionnaire, SLAQ) and damage (Lupus Damage Index Questionnaire, LDIQ). CRNA was based on questions derived from the National Health Interview Survey and considered positive if participants reported any of the following actions to save money in the last 12 months: skipping doses, taking less medicine, and/or delaying filling prescriptions. We performed multivariable linear regression to examine the associations between CRNA and lupus activity and damage, adjusted for the following covariates: age, sex, race, health insurance type, education levels, household income below the US median, PROMIS-Depression, PROMIS-Anxiety, fulfillment of fibromyalgia survey criteria, and SLE duration.

Results: 462 SLE participants completed the study visit: 430 (93.1%) female, 208 (45%) black, and mean age 53.3 years. Of the 462 SLE cases, CRNA was reported by 100 (21.7%) for the preceding 12 months. Based on multivariable models, CRNA was associated with both higher levels of SLE activity and damage scores, after adjustment for covariates (Table 1): those reporting CRNA had SLAQ scores that were on average 2.7 points higher compared those not reporting deviation [β coeff 2.7 (95% CI 1.3, 4.1), p< 0.001] and LDIQ scores that were 1.4 points higher [β coeff 1.4 (95% CI 0.5, 2.4), p=0.003]. Non-white race, having Medicaid/Medicare (compared to private insurance), and fulfilling FM survey criteria were also associated with both higher SLAQ and LDIQ scores; female sex was further associated with higher SLAQ scores (Table 1).

Conclusion: SLE patients with CRNA in the last 12 months had higher disease activity and damage scores. Asking patients about financial barriers, using tools such as motivational interviewing to discuss medication adherence, and incorporating cost-related factors in shared decision making are likely meaningful avenues for improving patient outcomes.


Table 1


Disclosure: D. Minhas, None; W. Marder, None; S. Harlow, None; H. Saltzman, None; A. Hassett, None; S. Zick, None; L. Wang, None; K. Barbour, None; C. Helmick, None; C. Gordon, Bristol-Myers Squibb, 5, 8, Centers for Disease Control and Prevention, 5, Eli Lilly, 5, 8, EMD Serono, 5, EMD Serono, UCB, 5, GlaxoSmithKline, 5, 8, Merck Serono, 5, 8, UCB, 2, 5, 8, Versus Arthritis/GSK, 2; W. McCune, None; E. Somers, None.

To cite this abstract in AMA style:

Minhas D, Marder W, Harlow S, Saltzman H, Hassett A, Zick S, Wang L, Barbour K, Helmick C, Gordon C, McCune W, Somers E. Cost-related Prescription Non-adherence Is Associated with Patient-reported Outcomes of Systemic Lupus Erythematosus Activity and Damage: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cost-related-prescription-non-adherence-is-associated-with-patient-reported-outcomes-of-systemic-lupus-erythematosus-activity-and-damage-the-michigan-lupus-epidemiology-surveillance-miles-coh/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cost-related-prescription-non-adherence-is-associated-with-patient-reported-outcomes-of-systemic-lupus-erythematosus-activity-and-damage-the-michigan-lupus-epidemiology-surveillance-miles-coh/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology